To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis. This combined approach – taking advantage of a series of validated markers – can be applied in monoplex or multiplex mode through conventional immunohistochemistry (IHC) or immunohistofluorescence (IHF).
Cell line markers for immunohistochemistry (IHC)
Name |
Species |
Markers |
ICI Markers | Human | CD8 / PDL1 |
TLS | Human | CD3 / CD20 |
TLS maturity | Human | CD3 / CD20 / CD23 |
Tumor_I | Human | CD163 / CD8 / CK7 |
Tumor_II | Human | CD163 / CD8 / CDX2 |
Cell line markers for immunohistofluorescence (IHF)
Name |
Species |
Markers |
B cells_I | Human | CD3 / CD20 / CD27 / Col1A1 / IgG / Mum1 |
B cells_II | Human | CD3 / CD20 / CD23 / Col1A1 / IgG / Mum1 |
Fibroblast_I | Human | CD45 / CD31 / CD248 / Col1A1 / ISLR / PDGFRα |
Fibroblast_II | Human | CD45 / CK7 / Col1A1 / PDL1 / TGFb1 / TGM2 |
Immuno_I | Human | CD3 / CD8 / Foxp3 / CD20 / PD1 / Granzyme B / Ki67 |
Immuno_II | Human | CD3 / CD56 / 4-1BB / TIGIT / PVR |
Immuno_III | Human | CD4 / CD8 / CD56 / Granzyme A / Foxp3 |
Metabolic_I | Human | CD45 / CD8 / Col1A1 / DDR1 / SLC7A11 / SLC3A2 |
Myeloid_Exhaustion | Human | CD33 / CD66b / CD68 / CD163 / PD1 / PDL1 / TIM3 / VISTA |
Myeloid_I | Human | CD1c / CD11c / CD68 / CD83 / HLA-DR |
Myeloid_II | Human | CD11b / CD15 / CD66b / CD163 / Arg1 / MPO |
Myeloid_III | Human | CD11b / CD11c / CD14 / CD45 / CD68 / cMAF / Elastase / MPO |
T cells_I | Human | CD45 / CD4 / CD8 / Foxp3 / Ki67 / PanCK |
T cells_II | Human | CD4 / CD8 / CD20 / CK7 / Foxp3 / ICOS / TIGIT |
T_Exhaustion_I | Human | CD3 / CTLA4 / PD1 / TIM3 / LAG3 / TIGIT |
T_Exhaustion_II | Human | CD8 / CD39 / CD45 / CK7 / LAG3 / PD1 / TIGIT / TIM3 |
T_NK_Exhaustion | Human | CD3 / CD56 / LAG3 / NKG2A / PD1 / TCRγδ / TIGIT / TIM3 |
Tfh | Human | CD4 / CD8 / CD20 / CXCR5 / cMAF / PD1 |
Tfh_Tfr | Human | CD4 / CD8 / CD45 / CD56 / CXCR5 / Foxp3 / ICOS / PD1 |
TLS activity | Human | CD4 / CD8 / CD20 / Ki67 / Foxp3 |
TLS maturity | Human | CD4 / CD8 / CD20 / CD21 / CD23 |
Tumor_I | Human | CD8 / CD163 / PD1 / PDL1 / IDO1 / PanCK |
Tumor_II | Human | CD8 / CD163 / PD1 / PDL1 / IDO1 / CK19 |
Tumor_III | Human | CD8 / CD163 / CD68 / cMAF / pSTAT1 / CK20 |
Tumor_IV | Human | CD8 / PDL1 / IDO1 / PanCK |
Angiogenesis | Mouse | HIF1α / CD31 / NG2 |
Immuno_I | Mouse | CD45 / CD8 / CD11b / Arg1 / PD1 / PDL1 |
Immuno_II | Mouse | CD45 / CD8 / Vimentin / F4/80 / PDL1 / PD1 |
Immuno_III | Mouse | CD45 / CD3 / Vimentin / F4/80 / PDL1 / PD1 |
Immuno_IV | Mouse | CD45 / CD4 / CD8 / Vimentin / PDL1 / PD1 |
Immuno_V | Mouse | CD45 / CD4 / CD8 / CD11b / Elastase / Foxp3 |
T cells | Mouse | CD45 / CD3 / CD4 / CD8 / Foxp3 / Vimentin |